These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 25584486)

  • 21. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.
    Tuominen R; Jewell R; van den Oord JJ; Wolter P; Stierner U; Lindholm C; Hertzman Johansson C; Lindén D; Johansson H; Frostvik Stolt M; Walker C; Snowden H; Newton-Bishop J; Hansson J; Egyházi Brage S
    Int J Cancer; 2015 Jun; 136(12):2844-53. PubMed ID: 25400033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
    Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
    Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temozolomide plus radiotherapy for glioblastoma in a Canadian province: efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation.
    Lam N; Chambers CR
    J Oncol Pharm Pract; 2012 Jun; 18(2):229-38. PubMed ID: 22065199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
    Paz MF; Yaya-Tur R; Rojas-Marcos I; Reynes G; Pollan M; Aguirre-Cruz L; García-Lopez JL; Piquer J; Safont MJ; Balaña C; Sanchez-Cespedes M; García-Villanueva M; Arribas L; Esteller M
    Clin Cancer Res; 2004 Aug; 10(15):4933-8. PubMed ID: 15297393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
    Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
    Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors.
    Krug S; Boch M; Rexin P; Gress TM; Michl P; Rinke A
    Anticancer Res; 2017 May; 37(5):2491-2500. PubMed ID: 28476818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment.
    Adachi J; Mishima K; Wakiya K; Suzuki T; Fukuoka K; Yanagisawa T; Matsutani M; Sasaki A; Nishikawa R
    J Neurooncol; 2012 Mar; 107(1):147-53. PubMed ID: 21968944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice.
    Dussol AS; Joly MO; Vercherat C; Forestier J; Hervieu V; Scoazec JY; Lombard-Bohas C; Walter T
    Cancer; 2015 Oct; 121(19):3428-34. PubMed ID: 26058464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
    Hochhauser D; Glynne-Jones R; Potter V; Grávalos C; Doyle TJ; Pathiraja K; Zhang Q; Zhang L; Sausville EA
    Mol Cancer Ther; 2013 May; 12(5):809-18. PubMed ID: 23443801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia.
    Medeiros BC; Kohrt HE; Gotlib J; Coutre SE; Zhang B; Arber DA; Zehnder JL
    Am J Hematol; 2012 Jan; 87(1):45-50. PubMed ID: 22052619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
    Esteller M; Garcia-Foncillas J; Andion E; Goodman SN; Hidalgo OF; Vanaclocha V; Baylin SB; Herman JG
    N Engl J Med; 2000 Nov; 343(19):1350-4. PubMed ID: 11070098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.
    McCormack AI; McDonald KL; Gill AJ; Clark SJ; Burt MG; Campbell KA; Braund WJ; Little NS; Cook RJ; Grossman AB; Robinson BG; Clifton-Bligh RJ
    Clin Endocrinol (Oxf); 2009 Aug; 71(2):226-33. PubMed ID: 19067722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
    Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of O⁶-methylguanine-DNA methyltransferase in childhood medulloblastoma.
    Faoro D; von Bueren AO; Shalaby T; Sciuscio D; Hürlimann ML; Arnold L; Gerber NU; Haybaeck J; Mittelbronn M; Rutkowski S; Hegi M; Grotzer MA
    J Neurooncol; 2011 May; 103(1):59-69. PubMed ID: 20820873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation between quantified promoter methylation and enzymatic activity of O6-methylguanine-DNA methyltransferase in glioblastomas.
    Kishida Y; Natsume A; Toda H; Toi Y; Motomura K; Koyama H; Matsuda K; Nakayama O; Sato M; Suzuki M; Kondo Y; Wakabayashi T
    Tumour Biol; 2012 Apr; 33(2):373-81. PubMed ID: 22274924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.
    Pietanza MC; Kadota K; Huberman K; Sima CS; Fiore JJ; Sumner DK; Travis WD; Heguy A; Ginsberg MS; Holodny AI; Chan TA; Rizvi NA; Azzoli CG; Riely GJ; Kris MG; Krug LM
    Clin Cancer Res; 2012 Feb; 18(4):1138-45. PubMed ID: 22228633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Critical appraisal of MGMT in digestive NET treated with alkylating agents.
    de Mestier L; Couvelard A; Blazevic A; Hentic O; de Herder WW; Rebours V; Paradis V; Ruszniewski P; Hofland LJ; Cros J
    Endocr Relat Cancer; 2020 Oct; 27(10):R391-R405. PubMed ID: 32698158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
    Sadones J; Michotte A; Veld P; Chaskis C; Sciot R; Menten J; Joossens EJ; Strauven T; D'Hondt LA; Sartenaer D; Califice SF; Bierau K; Svensson C; De Grève J; Neyns B
    Eur J Cancer; 2009 Jan; 45(1):146-53. PubMed ID: 18945611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.